KRAS and colorectal carcinoma: To this end, we selected paired plasma and FFPE tissues from mismatch repair proficient CRC tumors with KRAS mutations at codon 12 or 13, exon 2 (Mut), or KRAS gene wild-type (WT), from which we were unable to get accurate results using a Q Exactive Orbitrap mass spectrometer, and CRC cells (low metastatic KM12C and high metastatic to liver KM12SM CRC cells) stably overexpressing SPRYD7, a gene previously described as involved in CRC carcinogenesis [31,43], to identify proteins dysregulated in CRC and in CRC patients associated with these alterations (KRAS mutation and SPRYD7 overexpression).